BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BioCentury | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

Wave Life Sciences Ltd. ’s latest data releases provide the fullest view to date into how the company synthesizes its stereopure oligos and the benefits that can be derived from the chemistry. But whether the...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
BioCentury | Feb 10, 2016
Company News

Management tracks

Immunology company Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) hired James Bucher as SVP and general counsel. Bucher was VP of corporate legal affairs and corporate compliance officer at Exelixis Inc. (NASDAQ:EXEL). Medgenics Inc. (NYSE-M:MDGN) promoted VP of...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

Pfizer Inc. is expanding its rare disease development toolkit to include technologies that act upstream of protein expression to treat the root cause of disease, with an emphasis on adeno-associated viral vectors to correct loss-of-function...
BioCentury | Oct 4, 2014
Financial News

Forbion raises EUR 92M toward FCF III

Forbion Capital Partners has raised the first EUR 92 million ($116.6 million) of a planned EUR 150-EUR 200 million fund, named FCF III. The firm said the final close could be more than 12 months...
BioCentury | Sep 8, 2014
Company News

Santaris, Roche deal

Roche completed its acquisition of partner Santaris for $250 million in cash up front and up to $200 million in undisclosed milestones. In January, Santaris and Roche partnered to discover and develop RNA-targeted drugs against...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
BioCentury | Aug 11, 2014
Finance

Leading with the LNA

Given a choice between an acquisition and taking a chance on an IPO, investors in Santaris Pharma A/S took the path of certainty offered by partner Roche (SIX:ROG; OTCQX:RHHBY). They will net a greater than...
Items per page:
1 - 10 of 145
BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BioCentury | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BioCentury | Sep 28, 2017
Product R&D

Wave’s purity progress

Wave Life Sciences Ltd. ’s latest data releases provide the fullest view to date into how the company synthesizes its stereopure oligos and the benefits that can be derived from the chemistry. But whether the...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
BioCentury | Feb 10, 2016
Company News

Management tracks

Immunology company Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) hired James Bucher as SVP and general counsel. Bucher was VP of corporate legal affairs and corporate compliance officer at Exelixis Inc. (NASDAQ:EXEL). Medgenics Inc. (NYSE-M:MDGN) promoted VP of...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

Pfizer Inc. is expanding its rare disease development toolkit to include technologies that act upstream of protein expression to treat the root cause of disease, with an emphasis on adeno-associated viral vectors to correct loss-of-function...
BioCentury | Oct 4, 2014
Financial News

Forbion raises EUR 92M toward FCF III

Forbion Capital Partners has raised the first EUR 92 million ($116.6 million) of a planned EUR 150-EUR 200 million fund, named FCF III. The firm said the final close could be more than 12 months...
BioCentury | Sep 8, 2014
Company News

Santaris, Roche deal

Roche completed its acquisition of partner Santaris for $250 million in cash up front and up to $200 million in undisclosed milestones. In January, Santaris and Roche partnered to discover and develop RNA-targeted drugs against...
BioCentury | Sep 1, 2014
Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
BioCentury | Aug 11, 2014
Finance

Leading with the LNA

Given a choice between an acquisition and taking a chance on an IPO, investors in Santaris Pharma A/S took the path of certainty offered by partner Roche (SIX:ROG; OTCQX:RHHBY). They will net a greater than...
Items per page:
1 - 10 of 145